Minute Insight: Huma Buys AstraZeneca’s Amaze Digital Health Platform For Chronic Disease
Executive Summary
The companies will continue to collaborate to expand the reach of AstraZeneca's Amaze platform for chronic disease while launching companion applications.
You may also be interested in...
Huma Granted Class II Clearance By FDA For Its Disease-Agnostic Platform
Huma’s platform is now the only remote patient monitoring platform approved in both the US and Europe that is able to aid clinicians in their work.
Speaking To AstraZeneca And Huma About Digital’s Value For Pharma
AstraZeneca has been working with Huma to develop a series of software-based tools for monitoring patients. Medtech Insight spoke to both companies about the value of these partnerships and the potential challenges.
Minute Insight: Pear Therapeutics Inks Agreement With SoftBank To Develop Japan-Focused Digital Therapeutic
Pear Therapeutics signed an agreement with SoftBank to develop a Japan-focused digital therapeutic, but regulatory questions remain.